Antisense & RNAi Therapeutics Market Size, Share &Trends Report

Antisense & RNAi Therapeutics Market Size, Share &Trends Analysis Report By Route of Administration (Pulmonary Delivery, Intravenous Injection), By Application (CVDs, Oncology), By Technology, And Segment Forecasts, 2019 - 2025

  • Published Date: Jun, 2019
  • Base Year for Estimate: 2018
  • Report ID: 978-1-68038-805-3
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2017
  • Number of Pages: 161

Industry Insights

The global antisense & RNAi therapeutics market size was estimated at USD 1.09 billion in 2018 and is expected to witness a CAGR of 7.5% during the forecast period. Antisense technology provides the opportunity to manipulate the gene expression and this is being considered as an effective treatment for various diseases. This opportunity is being cashed on by the companies and are investing in R&D in this sector.

The possibility of studying of gene function for disease management by regulating the gene expression by the malfunctioning gene, R&D carried out with respect to treatment of uncommon neurodegenerative diseases, such as hereditary ATTR amyloidosis, are some of the other factors anticipated to drive the market.

Japan antisense & RNAi therapeutics Market

Antisense and RNAi therapeutics enable specific and highly effective gene silencing, based on this factor, a fair number of gene silencing drugs are in the late-stage of development. Market is expected to grow in the forecast period owing to a number of companies that are into the development of molecules based on antisense technology.

Collaboration activities between the pharmaceutical companies and Contract Research Organizations (CROs) working on drug delivery are expected to have a positive impact for the antisense & RNAi therapeutics market growth. However, overcoming the challenges like unpredictable activity from the molecules and other delivery-related complications would prove to be the market changing development of antisense therapeutics.

In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) initiated Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals for the treatment of Hepatitis’s B viral infection. Another collaboration by Ionis pharmaceuticals with Akcea Therapeutics has led to the approval of the world’s first antisense-based molecule “Tegsdi” by the FDA and the European Commission in 2018.

However, there are many challenges associated with the emerging antisense technology (and RNAi). One of the prominent bottleneck is the drug delivery to the intended site. Drug delivery to the nervous tissues is one of the problems as the drug has to pass the blood-brain barrier. Companies are coming up with solutions to overcome these challenges.

The toxic effects caused is another challenge for the use of this technology. Determining the right dosage and vector for drug delivery of an antisense molecule is one of the most important steps to ensure the safe administration. Companies have also faced rejections from the regulatory bodies. For instance, Akcea’s Waylivra, an antisense molecule to treat familial chylomicronemia syndrome was rejected by the FDA. These factors would push companies to develop better vectors, delivery solutions, and compositions.

Technology Insights

Antisense RNA has led the market in terms of revenue generation. These molecules are being tested to prevent disease onset and to halt the disease progression. Recent studies have shown that molecules with the use of antisense technology being trailed for spinal muscular atrophy and amyotrophic lateral sclerosis have shown promising results. Additionally, many other antisense technologies and oligonucleotide molecules are being tested for the treatment of non-neurodegenerative disorders. For instance, antisense-mediated exon skipping for Duchenne muscular dystrophy.

Application Insights

Rising need for the cure and prevention of diseases like cancer, HIV, and other diseases caused by mutating viruses is anticipated to influence the usage rate of oligonucleotide products. Increasing number of clinical trials for the oligonucleotide drugs, exhibits that the field is rapidly expanding. For instance, Ionis Pharmaceuticals alone has 4 molecules in pipeline and 2 approved molecules in the European Union and 1 in U.S.

Substantial pipeline for cancer therapies by companies and institutes such as Enzon Pharmaceuticals (Santaris Pharma), University of Texas, OncoGenex, Isarna Therapeutics, Astrazeneca (Ionis Pharmaceuticals), and INSYS Therapeutics, Inc. are expected to drive market. In addition, many companies have invested in R&D for nanocarriers to deliver oligonucleotides for cancer treatment, which is expected to contribute for the cancer management.

Nanocarriers can minimize the toxicity of these oligonucleotides. However, considerable bottlenecks of this nanoparticle systems is that they are influenced by inter and intra-tumor heterogeneity. This in turn has increased the need for efficient tumor targeting vectorization systems and multiple gene targeting oligonucleotide drugs. This need for newer and safer delivery systems for cancer and other viral disease management is expected to propel the market growth.

Route of Administration Insights

Route of administration is one of the most important aspects of any genetically modified molecule. The efficacy of these molecules varies based on the method of administration, vector used for the genetically modified molecule, type of molecule for injection. Most of the studies that in progress use largely employ attenuated viral particles or bacterial cells and are injected intravenously for the treatment.

Global antisense & RNAi therapeutics Market

Scientists are developing novel delivery systems like nanocarriers, to promote the in-vivo delivery of the oligonucleotides. Nanocarriers are known to enhance the bioavailability, carrying capacity of siRNA payload and they provide high interaction with the target cells. Another advantage of nanoparticles as carriers is that according to their charge they can interact with blood proteins to incite toxicity or even affect biodistribution.

Regional Insights

The U.S. has a number of RNAi therapeutics that are in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected growth in revenue that this market can have over the forecast period. For instance, AstraZeneca’s agreement with Ionis pharmaceuticals is one of the big deals that are investing heavily into antisense technology

Since the discovery of RNAi in, there have been numerous avenues of treatment development using RNAi, however, the market has picked up very little over the past decade due to the complexities in delivery methodologies related to RNAi. Development of newer nanotechnology-oriented methods has re-infused the market with a high potential to grow over the forecast period.

A number of drug candidates under clinical trials have shown favorable results and are progressing through the development phases. Assuming that such trials continue to show positive results, it can be expected that the North American market will witness considerable growth in demand over the forecast period.

Antisense & RNAi Therapeutics Market Share Insights

GSK, Sanofi-Genzyme, Alnylam Pharmaceuticals, Marina Biosciences, and Benitec Biopharma are some prominent companies in this market. These companies are involved in the development of RNAi therapies and platforms that offer medicines, diagnostics, and personalized treatment options for key diseases. Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Akcea Therapeutics, Quark Pharmaceuticals, and Gene Signal are several other companies with stronger pipeline portfolio.

Report Scope

Attribute

Details

Base year for estimation

2018

Actual estimates/Historical data

2014 - 2017

Forecast period

2019 - 2025

Market representation

Revenue in USD Million and CAGR from 2019 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., Japan, China, Brazil, and South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5-analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global antisense & RNAi therapeutics market report on the basis technology, application, route of administration, and region:

  • Technology Outlook (Revenue, USD Million, 2014-2025)

    • RNA Interference

      • siRNA

      • miRNA

    • Antisense RNA

  • Application Outlook (Revenue, USD Million, 2014-2025)
    • Oncology

    • Cardiovascular Diseases (CVDs)

    • Respiratory Disorders

    • Renal Diseases

    • Neurodegenerative Disorders

    • Genetic Disorders

    • Infectious Diseases

    • Other

  • Route of Administration Outlook (Revenue, USD Million, 2014-2025)
    • Pulmonary Delivery

    • Intravenous Injections

    • Intra-dermal Injections

    • Intraperitoneal Injections

    • Topical Delivery

    • Other Delivery Methods

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

    • Latin America

      • Brazil

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified